Home pageHDP1 • FRA
add
Arrowhead Research Corporation
Chiusura precedente
25,85 €
Intervallo giornaliero
25,67 € - 25,67 €
Intervallo annuale
19,52 € - 36,69 €
Cap di mercato
3,58 Mrd USD
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Entrate | — | — |
Spese di gestione | 126,19 Mln | 28,63% |
Utile netto | -125,30 Mln | -357,42% |
Margine di profitto netto | — | — |
Utili per azione | -1,02 | -326,67% |
EBITDA | -121,67 Mln | -339,34% |
Aliquota fiscale effettiva | — | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 520,91 Mln | 8,30% |
Totale attivo | 955,15 Mln | 7,16% |
Totale passivo | 459,74 Mln | 7,87% |
Patrimonio netto totale | 495,40 Mln | — |
Azioni in circolazione | 124,20 Mln | — |
Prezzo/valore contabile | 6,63 | — |
Redditività dell'attivo | -39,90% | — |
Rendimento sul capitale | -43,18% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | mar 2024info | Variazione Y/Y |
---|---|---|
Utile netto | -125,30 Mln | -357,42% |
Liquidità di esercizio | -92,38 Mln | -191,68% |
Contanti da investimenti | -268,94 Mln | -645,70% |
Contanti da finanziamenti | 430,78 Mln | 82.741,73% |
Flusso di cassa netto | 69,49 Mln | 203,27% |
Flusso di cassa libero | -91,82 Mln | -262,49% |
Informazioni
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Fondazione
1 gen 2004
Sito web
Dipendenti
525